Fig. 1 · Structure

Documents & Downloads

Bupivacaine HCl

Cat. No. A10168 CAS 18010-40-7
Bupivacaine is a more potent inhibitor of cAMP production than are chemically related local anesthetics that are less prone to produce cardiovascular toxicity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Sodium channel

Bupivacaine HCl Research Summary

This section summarizes 1 in vivo study of Bupivacaine HCl from 1 published reference.

Bupivacaine HCl In Vivo Studies

In rats, single sciatic injections of 0.5% and 1.31% (w/v) bupivacaine HCl produced median sensory-block durations of 120 and 210 minutes. Both concentrations were associated with local muscle injury. The higher concentration increased withdrawal latency in the uninjected limb, consistent with systemic drug effects. No nerve-structure changes were detected by qualitative histology at 4 or 14 days; quantitative neurotoxicity analysis was not performed. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Sciatic nerve blockade and local tissue response to bupivacaine HCl in rats

Animal study · Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block [1]

Single injections of unencapsulated HCl produced thermal sensory blockade, with muscle injury and inflammation on subsequent histology. The higher HCl concentration also increased contralateral thermal latency. No nerve-structure changes were detected by the study’s qualitative histology. Behavioral testing and tissue harvesting are retained together as one model study, with their different sample sizes explicit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Thermal nociceptive block duration; return of withdrawal latency from above to 7 sMedian (25th–75th percentiles), minutes 0.5% HCl: 120 (120–165); 1.31% HCl: 210 (180–240); Exparel: 240 (240–240); n=10 per group[1]
Contralateral paw withdrawal latency after 1.31% HCl versus baselineMedian (25th–75th percentiles), seconds Baseline 2.7 (2.3–3.1); peak 4.4 (3.4–4.8); P=0.005[1]
Local muscle injury at day 4 and day 14Median (25th–75th percentiles), ordinal score 0–6 0.5% HCl: day 4, 3.0 (3.0–4.0); day 14, 1.5 (1.0–2.0). 1.31% HCl: day 4, 5.0 (3.8–5.0); day 14, 3.0 (1.8–4.0). n=6 per group per time point.[1]
Axonal density, myelin structure and perineural tissue at 4 and 14 daysQualitative histology No significant structural changes observed in any treatment group; quantitative neurotoxicity analysis not performed[1]

Conditions shared by the study groups

Route
Injection at sciatic nerve
Frequency
Once
Treatment course
Single administration; histology at days 4 and 14
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
0.5% (w/v) bupivacaine HCl
0.6 mL; approximately 10 mg/kg, as reported
Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described.Median thermal block 120 (120–165) min; muscle injury detected; no significant contralateral deficit (P=0.31).[1]
1.31% (w/v) bupivacaine HCl
0.6 mL; approximately 25 mg/kg, as reported
Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described.Median thermal block 210 (180–240) min; muscle injury detected; contralateral latency increased (P=0.005).[1]
Exparel formulation comparator
0.6 mL; approximately 25 mg/kg total bupivacaine, as reported
Other formulation groups; uninjected contralateral limb for systemic-effect testing; normal uninjected nerve illustrated in Figure 5D. No saline-injection histology group described.Median thermal block 240 (240–240) min; myotoxicity scores 2.5 (1.0–3.3) at day 4 and 1.0 (1.0–2.0) at day 14; n=6/group/time for histology.[1]
0.5% (w/v) bupivacaine HCl
Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
1.31% (w/v) bupivacaine HCl
Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
Exparel formulation comparator
Model: Adult male Sprague-Dawley rats, 310–420 g; sciatic nerve block
Vehicle: 0.9% sodium chloride suspension
Reported limits: Behavioral n=10/group; histology n=6/group/time. The cohort overlap is not stated. No matched saline-injection histology control.
Methods and source locations

Compound reported in the paper: Bupivacaine hydrochloride; Compound label in the paper: Unencapsulated HCl solutions; Exparel is a separate formulation comparator

Rat HCl solution experiments only; no clinical dosing recommendation, salt conversion or Adooq lot validation.

Materials and Methods: Materials, Animal Care, Sciatic Blockade Technique, Assessment of Nerve Blockade, Tissue Harvesting and Histology, Statistical Analysis; Results: Duration of sciatic nerve blockade; Systemic distribution of bupivacaine; Tissue Reaction; Tables 1 and 2; Figures 4 and 5

Thermal nociceptive block duration; return of withdrawal latency from above to 7 s: 56°C hotplate; 12 s safety cutoff; uninjected limb assesses systemic effects. Planned comparisons were Exparel versus each HCl group (P=0.001 and 0.013 respectively); no HCl-versus-HCl P value adopted. — Methods: Assessment of Nerve Blockade and Statistical Analysis; Results: Duration of sciatic nerve blockade; Table 1

Contralateral paw withdrawal latency after 1.31% HCl versus baseline: Uninjected limb thermal testing used as a functional proxy for systemic distribution, not a plasma concentration assay. No significant deficits detected with 0.5% HCl (P=0.31) or Exparel (P=1.00). — Results: Systemic distribution of bupivacaine; Methods: Assessment of Nerve Blockade

Local muscle injury at day 4 and day 14: H&E-stained muscle; scoring based on depth/extent of nuclear internalization and regeneration. Table 2 P values compare each HCl group with Exparel, not the two HCl groups directly. — Methods: Tissue Harvesting and Histology; Results: Tissue Reaction; Table 2; Figure 4B,C,E,F,I,J,L,M

Axonal density, myelin structure and perineural tissue at 4 and 14 days: Epon-embedded nerve, 0.5 μm toluidine-blue sections; Figure 5 includes normal uninjected nerve. This is not proof of absence of all neurotoxicity. — Methods: Tissue Harvesting and Histology; Results: Tissue Reaction, final paragraph; Figure 5A–D and caption

0.5% (w/v) bupivacaine HCl · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5

1.31% (w/v) bupivacaine HCl · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5

Exparel formulation comparator · Methods: Sciatic Blockade Technique; Results: Duration of sciatic nerve blockade, Systemic distribution, Tissue Reaction; Tables 1 and 2; Figure 5

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 18010-40-7
Formula C18H28N2O.HCl
Molecular Weight 324.9
Synonyms Marcain; Marcaine; Sensorcaine; Vivacaine
SMILES
CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (184.67 mM)
Water 21 mg/mL (64.63 mM)
Ethanol 60 mg/mL (184.67 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bupivacaine HCl Research References

  1. [1] J Brian McAlvin, Robert F Padera, Sahadev A Shankarappa, et al. Multivesicular liposomal bupivacaine at the sciatic nerve Biomaterials (2014). PMID: 24612918 DOI: 10.1016/j.biomaterials.2014.02.015 Source material

Added to your cart

View Cart Checkout
Loading...